Pilocytic astrocytomas (PAs, WHO grade I) are the most common brain tumors in the pediatric and adolescent population, accounting for approximately one-fifth of central nervous system tumors. Because few consistent molecular alterations have been identified in PAs compared to higher grade gliomas, we performed array comparative genomic hybridization using two independent commercial array platforms. Although whole chromosomal gains and losses were not observed, a 1-Mb amplified region of 7q34 was detected in multiple patient samples using both array platforms. Copy-number gain was confirmed in an independent tumor sample set by quantitative PCR, and this amplification was correlated to both increased mRNA and protein expression of HIPK2, a homeobox-interacting protein kinase associated with malignancy, contained within this locus. Furthermore, overexpression of wild-type HIPK2, but not a kinaseinactive mutant, in a glioma cell line conferred a growth advantage in vitro. Collectively, these results illustrate the power and necessity of implementing high-resolution, multiple-platform genomic analyses to discover small and subtle, but functionally significant, genomic alterations associated with low-grade tumor formation and growth. Oncogene (2008) 27, 4745-4751; doi:10.1038 /onc.2008 published online 14 April 2008 Keywords: pilocytic astrocytomas; aCGH; HIPK2 amplification Astrocytic tumors (gliomas) are the most common primary glial neoplasm affecting children and young adults, accounting for 16-21% of central nervous system tumors in individuals less than 19 years of age. These low-grade tumors exhibit rare mitotic figures, but often have microvascular proliferation and microglial infiltration. In contrast to other astrocytic neoplasms, pilocytic astrocytomas (PAs) rarely progress to more malignant gliomas and have even been reported to regress without treatment when they occur in patients with neurofibromatosis-1. This characteristic behavior implies that PA may be a molecularly distinct glial neoplasm.
The unique clinical behavior of PAs is also reflected in the infrequent identification of genomic/genetic changes in these tumors. Although TP53 and PTEN mutations are common in higher grade gliomas (Cheng et al., 2000; Tada et al., 2003; Arjona et al., 2006) , these genes are rarely altered in PA (Ishii et al., 1998; Hayes et al., 1999; Cheng et al., 2000; von Deimling et al., 2000; Wemmert et al., 2006) . Similarly, although chromosomal aberrations or amplification/deletion of specific genes related to cell cycle control, growth factor receptors and signal transduction pathways are commonly identified in other glioma subtypes (Koschny et al., 2002; Schmidt et al., 2002; Ohgaki et al., 2004; Ohgaki, 2005) , most cytogenetic studies have shown that the majority of PAs have normal karyotypes. Structural aberrations involving chromosomes 6, 7, 8, 11, 17 and 19 have been reported in a few cases (Jenkins et al., 1989; Thiel et al., 1992; Agamanolis and Malone, 1995) , and the most consistently identified cytogenetic changes involve gains on chromosomes 7 and 8 (White et al., 1995; Zattara-Cannoni et al., 1998; Sanoudou et al., 2000; Jones et al., 2006) . We have previously identified a transcript on chromosome 8 whose expression is increased in PA (Sharma et al., 2006) ; however, no specific genes have been implicated on chromosome 7.
In an effort to identify recurrent PA-associated genetic abnormalities in a more comprehensive manner, we employed high-resolution, array comparative genomic hybridization (aCGH) using two different array platforms from NimbleGen and Affymetrix at a resolution of approximately 6 and 2.5 kb, respectively.
Ten patient-matched cerebellar PAs and germline DNA sample pairs from patients with age less than 18 years were selected for this study. These tumors were specifically chosen based on their common histologic appearance and similar brain location and patient age. All samples were subject to simultaneous aCGH using a 385K high-resolution NimbleGen oligonucleotide array and the Affymetrix Mapping 500K SNP Array Set. To visualize large, contiguous amplifications and deletions across the genome, individual probe-level copy-number values of the tumors were plotted after internally normalizing each tumor to its germline control (Figure 1 ). Although most samples did not have chromosome-wide copy number gains or losses, a single sample (patient ID 963) had a copy number gain of many single-nucleotide polymorphism (SNP) markers on chromosomes 6 and 21 that was confirmed by segmentation analysis of the NimbleGen data. Thus, no recurrent, large-scale amplifications or deletions were observed consistently on both array platforms in the PA sample set, a result previously confirmed by lower resolution cytogenetic-based studies.
Although multiple focal abnormalities in individual cases were observed on either platform (Figure 1 ), it was difficult to discern regions which were recurrently amplified or deleted in PAs consistently across both technologies based on visual inspection alone. Thus, copy number results from both dChip and CNAT algorithms were first combined to identify SNP markers that were called amplified or deleted in more than one sample. A total of 118 SNP markers on chromosome 7 and 23 markers on chromosomes 1, 7, 12, 15 and 21 were recurrently amplified or deleted, respectively, by both tools (Supplementary Table 1, Supplementary Data). Next, to identify bona fide regions of recurrent amplification and deletion, segment-level results from each corresponding NimbleGen array were co-analyzed with segment-level results from dChip, CNAT and CNAG ( Figure 2a ). Although no deletions were observed by segment-level analysis, a single region on 7q34 (chromosome 7: 138 151 200-139 456 000, NCBI build 35) was amplified in 8 out of 10 patient-matched tumor-germline samples ( Figure 2a , 'SNP Segments'). This same region was found amplified in 6 out of 10 samples by NimbleGen aCGH (Figure 2a , 'aCGH'). The most frequently amplified SNP and aCGH segments were localized to the upstream region of the homeodomain-interacting protein kinase 2 (HIPK2) gene.
To validate HIPK2 amplification in PA, quantitative PCR (qPCR) was performed using matched peripheral blood cell and tumor DNAs from the original PA sample set as well as from an independent set of 61 PAs. The cutoff for HIPK2 gain/loss in the tumor samples was set using the mean HIPK2 copy number (2.03)±3 standard deviations (0.11) from the 10 peripheral blood cell samples (Konigshoff et al., 2003) . Using these criteria (that is HIPK2 > ¼ 2.37 to be called a gain or HIPK2 o ¼ 1.68 to be called a loss), 60% (6/10) of tumors in the original PA sample set had a HIPK2 copy number gain, and this level of amplification was comparable to that observed in both array-based platforms ( Figure 2b ). Importantly, this finding was confirmed in the independent set where 42.6% (26/61) of these tumors had HIPK2 amplification (mean ¼ 2.6-fold amplification) (Figure 3a) . Quantitative RT-PCR and co-analysis of copy number and microarray expression data further confirmed that HIPK2 gene amplification correlated with increased HIPK2 mRNA levels in the same tumor (Supplementary Figure 1, Supplementary  Data) .
To determine whether the increase in HIPK2 copy number and RNA expression was observed also at the protein level, immunohistochemistry on brain tumor specimens was performed using three separate tissue microarrays. First, using a tissue microarray containing normal brain and PAs, 41/63 (65%) of PA specimens exhibited increased HIPK2 expression relative to normal brain. Positive HIPK2 immunostaining was defined as greater than 25% of the tumor cells with nuclear HIPK2 expression. Eighty percentage of the PAs that scored positive by this criteria actually contained greater than 75% tumor cells with nuclear HIPK2 expression (Figure 3b panels i-iv) . These results were highly reproducible in that we observed a 90% concordance in immunostaining among multiple cores from the same tumor represented on the tissue microarray. In contrast to the high level of HIPK2 expression observed in PAs (WHO grade I glioma), significantly lower levels of HIPK2 immunopositivity were observed in other glioma subtypes and histological grades. In this regard, 23 and 27% of the grade III (anaplastic astrocytoma) and IV (glioblastoma multiforme) gliomas, respectively, and 12% of oligodendrogliomas exhibited HIPK2 overexpression relative to non-malignant brain tissue. We observed no HIPK2 overexpression in ependymomas. These results demonstrate that HIPK2 is overexpressed in a large proportion of PAs compared to other glial tumors; however, HIPK2 overexpression is not a specific signature of PAs.
To determine whether HIPK2 overexpression confers a growth advantage in vitro, we performed clonogenic assays using U87 human glioma cells, which demonstrate a low level of endogenous HIPK2 expression (data not shown). Equal numbers of U87 cells were transfected with either empty vector, active HIPK2 or a kinase-inactivated HIPK2 mutant (K221R) (D'Orazi et al., 2002) along with a plasmid containing antibiotic resistance. Consistent with the prediction that HIPK2 promotes cell growth, we observed a 1.8-fold increase (mean of three independent experiments) in the number of colonies following HIPK2 overexpression (Figure 4) . There was no effect of kinase-inactivated HIPK2 mutant or empty vector overexpression on U87 colony formation.
The observation that HIPK2 overexpression leads to increased cell growth in a glioma cell line is interesting in light of the reported roles of HIPK2 in growth regulation. HIPK2 is a serine/threonine kinase that functions as a transcriptional regulator by multiple mechanisms. First, it acts as a co-repressor by directly interacting with transcription factors such as Brn3a (Wiggins et al., 2004) and c-Ski (Harada et al., 2003 Figure 1 DNAs from 10 patient-matched PAs and peripheral blood leukocytes were extracted, labeled and hybridized to NimbleGen '2006-02-14_HG17_WG_CGH' arrays (Human genome build 17, National Center for Biotechnology Information build 35) and to Affymetrix GeneChip Human Mapping 500K array sets. After scanning and quantification of signal intensities were performed, tumor copy number was plotted using NimbleGen (unaveraged, Z-score normalized probe level data (a)) and Affymetrix (dChip-derived copy number data (b)) data. The magnitude of amplifications and deletions in the tumor genome is color-coded using a gradient from green or red, respectively, to white. CGH, comparative genomic hybridization; PA, pilocytic astrocytoma. Figure 2 (a) Detailed view of the 7q34 locus amplified in multiple samples. SNP markers and segments identified using the Affymetrix and NimbleGen array data are shown from left to right. Amplified SNP markers are shown in black whereas non-amplified SNP markers are shown in gray. Genes in the region are displayed on the far right. CGH-segMNT was used to identify amplified and deleted segments using the NimbleGen data. For Affymetrix data, copy number analysis was performed using dChip (Lin et al., 2004) , CNAG (Nannya et al., 2005) and the Copy Number Analysis Tool (CNAT). To facilitate cross-platform comparison, probes from both array platforms were mapped to NCBI Build 35, and SNP marker data were converted to segment data using DNAcopy (Venkatraman and Olshen, 2007) . Recurrent, minimally overlapping regions were identified by analyzing segments identified using either array platform. induces or represses apoptosis, inhibits cell proliferation, regulates segmental identity and is crucial for hematopoiesis. Figure 3 (a) DNA qPCR-based HIPK2 copy number data are plotted for matched peripheral blood cells (10-PBC) and tumor DNAs (10-PA) of the 10 PA patients and 61 independent PAs (61-PA). The cutoff for DNA copy number was set using the mean ± 3 s.d. of the copy numbers derived from the 10 PBC samples. A 20-ml reaction mixture for qPCR was composed of 10 ml of 2 Â TaqMan universal PCR master mix (Applied Biosystems Inc.), 10 ml of primer and probe mix (600 nM each forward and reverse primers, 200 nM specific TaqMan probe at final concentration) and 10 ng of DNA. All real-time PCR assays were performed in triplicate on an ABI PRISM 7900HT Sequence Detector System (ABI) as follows: 50 1C for 2 min, 95 1C for 10 min and 40 cycles of both 15 s at 95 1C and 60 sec at 60 1C. The reference gene, DOCK10, which was chosen to normalize the DNA input between individual DNA samples, is on chromosome 2 where no significant gains/losses were observed with both NimbleGen and Affymetrix array data in our 10 PA cases and in another study (Jones et al., 2006) . (b) The upper panel demonstrates representative PAs with different percentages of cells within the tumor demonstrating HIPK2 nuclear staining; (i) >75%; (ii) 50-75%; (iii) 25-50%; (iv) o25% (scale, 100 mm). The lower panel lists the number and percentage of tumors with positive staining for HIPK2 where positive nuclear staining was observed in >25% of the cells in the tumor specimen. Higher rates of positive nuclear staining for HIPK2 were observed in PAs than in higher grade astrocytomas or other tumors of neurological origin. HIPK2 immunohistochemistry was performed on glioma tissue microarrays after antigen retrieval, and slides were hematoxylin-counterstained prior to determining positive staining (See Supplementary Methods for further details). PA, pilocytic astrocytoma; qPCR, quantitative PCR.
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Functional studies have demonstrated that HIPK2 functions as a tumor suppressor in some cell types (Pierantoni et al., 2002; Wei et al., 2007) . However, in the central nervous system, Hipk2 loss leads to selective loss of midbrain dopamine neurons as a result of increased apoptosis mediated by the inability of the receptor-activated Smads (for example, Smad2 and Smad3) to regulate transcription in response to TGFb3 . Consistent with our results, HIPK2 overexpression leads to increased glioma cell growth in vitro. Further studies will be required to define the mechanism underlying HIPK2-positive growth regulation in astrocytes and glioma cells.
This study leverages significant advances both in experimental design and in technology platform to identify subtle genomic imbalances that may occur in low-grade malignancies such as PAs. First, the use of patient-matched germline and tumor DNA permitted us to clearly distinguish somatic amplifications and deletions from a multitude of possible germline copy number variations that would be detected using an unrelated 'normal' reference pool (Sebat et al., 2004) . Second, the utilization of two independent, highresolution genome-wide array platforms enabled the identification of small, subtle alterations with increased confidence. In striking contrast to patterns of 10-to 50-fold amplification of genes observed in other tumors (Albertson, 2006) , the low, but functionally significant amplification of HIPK2 in PA (average copy number ¼ 2.57 by qPCR) would likely be missed or discounted as 'noise' in studies that utilize lower resolution array designs or a single-array platform. Although the low level of HIPK2 amplification observed may reflect an averaged value of inherent tumor genome heterogeneity, it is also possible that such small quantitative copy number increases of regulatory genes, like HIPK2, may result in significant perturbations of downstream targets that contribute to the pathophysiology of PAs. The paucity of genomic alterations that were found in our sample set may indicate that only a few genes drive the tumorigenic process of PA or that other mechanisms such as gene methylation or sequence mutation may be more prevalent in these tumors. In summary, our study highlights the need to employ comprehensive and complementary technologies to identify subtle copy number changes that underlie the molecular pathogenesis of low-grade tumors. ) per well were co-transfected with 2 mg of equimolar amounts of pCMV-HIPK2, pCMV-HIPK2 m (K221R) or empty vector in combination with pBABE-puro (Addgene, Cambridge, MA, USA) using the Fugene 6 reagent (Roche Diagnostics, Indianapolis, IN, USA) before selection with puromycin (0.7 mg/ml; Sigma-Aldrich, St Louis, MO, USA) for 14-21 days. Surviving colonies were stained with crystal violet and counted. Representative plates of HIPK2, HIPK2 m or empty vector transfections are shown. (b) Average clone counts across three independent experiments are plotted. Statistical significance among different groups was analyzed by one-way ANOVA followed by Bonferroni's test. A P-value o0.05 was considered significant. Statistically significant differences were noted between HIPK2-transfected cells and either vector or HIPK2 m -transfected cells.
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